Unlocking Chronic Diseases with Next-Gen i-body Platform Technology from AdAlta (1AD)
Unlocking Chronic Diseases with Next-Gen i-body Platform Technology from AdAlta (1AD)
1AD stock carries a dramatically undervalued profile against its blue-sky upside target
Emerging Growth Report...
$1.87 million raised in oversubscribed Shortfall facility
MELBOURNE Australia, 13 July 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is pleased...
New AD-214 Data Links Phase I Results With Efficacy; De-Risks Clinical Dosing Schedule
Key points:
• New data favourably links AD-214 preclinical animal studies and Phase I human
clinical trial results to provide important dose frequency insights
• AD-214 is designed to...
AdAlta (ASX: 1AD) IMPORTANT PHASE I EXTENSION CLINICAL STUDY OF AD-214 APPROVED
29 June 2023
ASX Announcement
IMPORTANT PHASE I EXTENSION CLINICAL STUDY OF AD-214 APPROVED
Key highlights:
Human Research Ethics Committee (HREC) has approved Phase I extension...